Moderna to run three new infectious disease vaccine development programs, EU vaccine distribution begins Moderna announced today that it is expanding its pipeline of innovative vaccines with three new development programs based on the clinical success of its infectious disease vaccine portfolio to date.
Those programs cover mRNA vaccine candidates against seasonal flu, HIV and the Nipah virus. The US biotech also announced an expansion of its respiratory syncytial virus (RSV) vaccine program into older adults.
Moderna currently has 24 mRNA development programs in its portfolio with 13 having entered the clinic. It said its
pipeline is organized into six modalities based on similar mRNA technologies, delivery technologies and manufacturing processes.